Effects of acetylsalicylic acid and indomethacin on growth hormone secretion in man. 1977

F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo

To investigate the possibility that prostaglandins (PG) take part in the control of growth hormone (GH) secretion in humans, we have studied the effects of protracted and acute administration of acetylsalicylic acid (ASA) and indomethacin (ID), two PG synthesis inhibitors, on basal and insulin-stimulated GH secretion in normal volunteers. In eight subjects, oral administration of 3-2 g daily of ASA for 4 days clearly reached GH response to insulin hypoglycemia (p less than 0.01, ANOVA). In six additional subjects, GH response to hypoglycemia was not modified by a 4-day oral treatment with 300 mg daily of ID. The pattern of plasma free fatty acids (FFA) and blood glucose during the insulin tolerance test was not significantly affected by ASA treatment. After ID the O time value of the above parameters was somewhat higher than under basal conditions, while the drop of blood glucose, but not to FFA, was slightly more pronounced. Acute oral administration of 1.5 g ASA in 12 subjects did not appreciably modify baseline plasma GH, FFA, and blood glucose levels. By contrast, a single oral dose of 100 mg ID in 12 subjects caused a moderate but significant rise (p less than 0.05) of plasma GH levels together with a clear elevation (p less than 0.01) of plasma FFA and blood glucose levels with respect to a group of controls treated with a placebo. Collectively these results are compatible with the possibility that PG play a physiologic stimulating role in the control of GH secretion, although an effect of ASA and ID unrelated to PG inhibition cannot be ruled out, In any event, in view of the number of endocrine and metabolic alterations induced by ASA and ID, these drugs seem to merit further study.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D011453 Prostaglandins A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes. Prostaglandin,Prostanoid,Prostanoids
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D005230 Fatty Acids, Nonesterified FATTY ACIDS found in the plasma that are complexed with SERUM ALBUMIN for transport. These fatty acids are not in glycerol ester form. Fatty Acids, Free,Free Fatty Acid,Free Fatty Acids,NEFA,Acid, Free Fatty,Acids, Free Fatty,Acids, Nonesterified Fatty,Fatty Acid, Free,Nonesterified Fatty Acids
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
October 1983, International journal of clinical pharmacology, therapy, and toxicology,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
June 1972, Metabolism: clinical and experimental,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
January 1973, Actualites de physiologie pathologique,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
January 1983, International journal of clinical pharmacology research,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
March 1994, The Journal of clinical endocrinology and metabolism,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
January 1981, Scandinavian journal of rheumatology,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
April 1981, European journal of clinical investigation,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
September 1977, Endocrinologia experimentalis,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
September 1990, The American journal of the medical sciences,
F Cavagnini, and A Di Landro, and C Invitti, and U Raggi, and P Alessandrini, and M Pinto, and G Girotti, and P Vigo
June 1990, International journal of clinical pharmacology, therapy, and toxicology,
Copied contents to your clipboard!